Sotagliflozin improves survival in patients of diabetes and worsening HF: Study
USA: The use of sotagliflozin increased days alive out of the hospital (DAOH) in type 2 diabetes (T2D) patients at high risk for recurrent hospitalization due to recent admission for worsening heart failure, suggests a recent study.
The findings, published in the journal Annals of Internal Medicine, are important because increased rates of death and re-hospitalization are significant components of disease burden in this patient population.
Sotagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor but also inhibits SGLT1, which primarily exists in the gut and appears to delay glucose absorption.
In the SOLOIST-WHF (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure) trial, sotagliflozin reduced total occurrences of cardiovascular deaths, hospitalizations for heart failure, and urgent visits for heart failure relative to placebo by 33 percent. In a prespecified analysis of the study, researchers from the University of Colorado Anschutz Medical Campus extended on previous findings by comparing DAOH between the sotagliflozin and placebo groups.
More than 1,000 patients with type 2 diabetes and reduced or preserved ejection fraction who were recently hospitalized for worsening heart failure were randomly assigned to take sotagliflozin or placebo to determine whether sotagliflozin increased the prespecified efficacy outcome of DAOH. The primary analysis included hospitalizations for any reason. The researchers found that the DAOH rate in the sotagliflozin group was 3 percent higher than in the placebo group, so that for every 100 days of follow-up, patients in the sotagliflozin group were alive and out of hospital 2.9 days more than patients in the placebo group.
According to the researchers, the study findings may provide additional patient-centered outcomes to capture the totality of disease burden and could have important implications for patient quality of life and health care costs.
Reference:
DOI: https://www.acpjournals.org/doi/10.7326/M21-0651
